Mots-clés
Organismes > OEDT
OEDTSynonyme(s)Observatoire européen des drogues et des toxicomanies European Monitoring Centre for Drugs and Drug Addiction |
Documents disponibles dans cette catégorie (436)
Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance AH-7921 (3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the [...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance MDPV (3,4-methylenedioxypyrovalerone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the EMCDDA and[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the availabl[...]Rapport
In May 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), through a joint assessment. The two organisations[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate, commonly known as 5F-MDMB-PINACA, through a joint asses[...]Rapport
In February 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate, commonly known as MDMB-CHMICA, through a joint assessment.[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as ADB-CHMINACA, through a joint [...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide, commonly known as AB-CHMINACA, through a joint asses[...]Rapport
In September 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, commonly known as acryloylfentanyl, through a joint assessment. The two organisations [...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl) isobutyramide, commonly known as 4-fluoroisobutyrylfentanyl (4F-iBF), through a joint ass[...]Rapport
In September 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (acetylfentanyl), through a joint assessment. The two organisations concluded that[...]Rapport
In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), through a joint assessment. The two organis[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]tetrahydrofuran-2-carboxamide, commonly known as tetrahydrofuranylfentanyl (THF-F), through a [...]Article : Périodique
B. PULVER ; S. FISCHMANN ; A. GALLEGOS ; R. CHRISTIE |Synthetic cannabinoids (SCs), often sold as "legal" replacements for cannabis, are the largest group of new psychoactive substances monitored by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Currently, close to 240 struct[...]Rapport
Isotonitazene is a synthetic opioid analgesic monitored by the EMCDDA as a new psychoactive substance through the European Union Early Warning System since 2019. Based on potential public health risks, an initial report has been prepared and sub[...]Rapport
Rapport
These guidelines provide the rationale, steps, procedures, roles, and responsibilities for the operation of the EU Early Warning System. They reflect the requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 20[...]Rapport
This paper is part of the EMCDDA activity around the development and improvement of drug supply indicators, with a focus on drug-related homicide. It builds upon the 2017 review of the academic research and data sources on drug-related homicide [...]Rapport
G. HAY ; N. McKEGANEY ; E. BIRKS ; L. WIESSING ; R. HARTNOLL ; P. Y. BELLO ; C. M. COMISKEY ; D. D'IPPOLITI ; A. DOMINGO-SALVANY ; FREIRE S. ; M. MOREIRA ; NORÉN A. ; PARTANEN P. ; POLITIKOU K. ; SEIDLER D. ; F. SMIT ; TOET J. ; A. UHL ; VIRTANEN A. | Lisbon : EMDCCA | 1997ENGLISH : This report presents the findings from an EMCDDA funded Methodological Pilot Study of Local Level Prevalence Estimates. Following on from a joint EMCDDA / Pompidou Group meeting, comparative pilot studies to improve the prevalence es[...]Rapport
Since the beginning of 2020, the world has been experiencing an unprecedented public health emergency caused by the coronavirus disease (COVID-19) pandemic, which has led to the progressive introduction of social distancing and other control mea[...]Rapport
FRANÇAIS : Depuis le début de l'année 2020, le monde connaît une situation sanitaire sans précédent causée par la pandémie de coronavirus (COVID-19), qui a conduit à l'introduction progressive de mesures de distanciation sociale et d'autres mes[...]Rapport
Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this outbreak for drug ser[...]Rapport
Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this pandemic for people w[...]Rapport
Brief interventions are psychosocial techniques designed to help recipients recognise harmful patterns of substance use, and to motivate and support them to address that use. Studies suggest that brief interventions in an emergency department ma[...]Rapport
Ce rapport tente de combler une partie du manque de connaissance sur le trafic, la consommation des drogues illicites et des médicaments psychotropes en Afrique. Il dresse un inventaire des organismes spécialisés intervenants dans le champ spéci[...]Rapport
FRANÇAIS : Le Rapport ESPAD 2015 présente les expériences et les perceptions des élèves concernant diverses substances, comme le tabac, l'alcool, les drogues illicites, les produit à inhaler, les médicaments et les nouvelles substances psychoa[...]Rapport
FRANÇAIS : L'usage de tabac et d'alcool chez les élèves de 15 à 16 ans donne des signes de déclin, mais la consommation potentiellement problématique de cannabis et les difficultés posées par les nouvelles conduites addictives soulèvent des in[...]Rapport
This study estimates how much 22 European countries spent on drug-law offenders in prisons during the last decade. Based on this, an estimate for public expenditure on drug-law offenders at the European level was made.Rapport
This report presents estimates of aggregate market size for the different drugs at EU and European level and describes in detail how these estimates were achieved. Country level estimates are not reported given the uncertainty around some of the[...]Rapport
This report includes estimates of the total size of the retail drug market in the European Union in 2017 for cannabis, heroin, cocaine, amphetamines and MDMA.Rapport
OEDT = EMCDDA ; A. SARASA-RENEDO ; G. BARRIO ; L. MONTANARI ; B. GUARITA ; L. DE LA FUENTE ; M. J. BRAVO ; J. VICENTE | Lisbon : OEDT / EMCDDA | Technical reports | 2015FRANÇAIS : Ce rapport décrit les tendances en matière d'injection de drogues dans les États membres de l'UE, la Norvège et la Turquie entre 2000 et 2011, à travers une analyse des données relatives aux personnes recevant un traitement médicamen[...]Rapport
L'étude a révélé que l'information non-gouvernementale relative à la problématique évoquée était fortement sous-exploitée, principalement par manque de ressources techniques et d'appuis méthodologiques adaptés. Trois principes fondamentaux ont é[...]Document multimédia
"EU Drug Market: Amphetamine" describes the European amphetamine market from production and trafficking, to distribution and use. It details the processes, materials and actors involved at different stages and levels of the market. Taking a thre[...]Rapport
This resource offers a strategic and top-level summary for policymakers and decision-makers, to support the development and implementation of policies and actions in Europe, based on a robust understanding of the current drug landscape and emerg[...]Document multimédia
'EU Drug Market: Cannabis' describes the European cannabis market from production and trafficking, to distribution and use. It details the processes, materials and players involved at different stages and levels of the market. The module takes a[...]Rapport
Document multimédia
What are the latest changes in the EU opioids market? How are global geopolitical developments impacting supply? Are heroin trafficking routes changing? To what extent do synthetic opioids pose a threat to Europe? These are among the issues expl[...]Rapport
Rapport
The EU Drug Markets Report 2019 is the third comprehensive overview of illicit drug markets in the European Union by the EMCDDA and Europol. The analysis presented in this report spans numerous topics such as the links between drugs and other cr[...]Rapport
FRANÇAIS : Le présent rapport analyse le phénomène du marché des drogues illicites dans le contexte plus large des nouvelles tendances en matière de consommation de drogue, des facteurs culturels et sociaux et des liens avec la criminalité. Les[...]Congrès
Euro-Ibero American seminar : cooperation on drugs and drug addiction policies. Conference proceedings (8-9 October 1998; Oporto) | Luxembourg : Office for Official Publications of the European Communities | 1999FRANÇAIS : Ce séminaire a eu lieu les 8 et 9 octobre 1998 au Portugal dans la perspective de la tenue imminente de 2 sommets réunissant les chefs des gouvernements d'Europe, d'Amérique Latine et des Caraïbes, sur les questions de coopération e[...]Chapitre
Nearly all European countries now frame their drug policy initiatives within an overall national drugs strategy or action plan. An in-depth analysis of drug policy in Europe in this Selected issue reveals a broadening of the scope of these drug [...]Livre
The drug control regime established by the international community has not succeeded in curbing either the demand for, or the offer of, narcotics. But, despite a series of developments in the Americas - including the legalisation of cannabis in [...]Rapport
The aim of this 'quick guide' is to make practical information on prevention quality standards available outside the European Union. A condensed version of EMCDDA Manual 7, it includes a description of the eight stages involved in the drug preve[...]Document multimédia
FRANÇAIS : La diversification de l'offre et de l'usage de drogues crée de nouvelles problématiques pour la politique en matière de drogue, de soins et de santé en Europe. [...] Ce rapport fournit la dernière vue d'ensemble existante de la situa[...]Rapport
In the last year, there has been decriminalisation of all drug use in Portugal, a Policy Note in Belgium to decriminalise cannabis possession, and the start of the process to downgrade the offence of cannabis possession in the UK. This brief rep[...]Rapport
This study aims to give a descriptive overview of the various legal mechanisms used to sanction this phenomenon - whether provisions exist in drug control laws or road traffic laws, the substances addressed, the status and levels of penalties, a[...]Rapport
When a new psychoactive substance appears on the market, legislators need to choose whether to bring it under control of the drug laws, and for public health reasons they may need to do so quickly. A comparative study of the systems and procedur[...]Rapport
This analysis describes and compares the different substances often referred to as "medicinal cannabis" and their methods of administration, as well as the various methods and levels of permission and control under international, EU and national[...]Rapport
This paper analyses primary studies that examine the consequences of drug law changes, and describes their approach and methodologies. They were categorised as changes to laws addressing illegal use and possession, changes in laws regulating leg[...]